WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company's humanized antibody, clivatuzumab, is specifically reactive with pancreatic ductal adenocarcinoma (PDAC) and does not react with chronic pancreatitis (CP) tissues. Dr. David V. Gold, Director of Laboratory Administration and Senior Member of the Garden State Cancer Center in Morris Plains, NJ, presented the study at the 2013 Annual Meeting of the American Association for Cancer Research in Washington, DC. "These data have strong implications for the clivatuzumab-based blood test, suggesting that individuals diagnosed with CP who are found to be positive for this blood test, may in fact have cancer, and should be followed closely for further indications of PDAC," commented Dr. Gold. The clivatuzumab-based blood test has previously been shown to correctly identify nearly two thirds of patients with early stage pancreatic cancer. (For more information, please refer to the Company press release at www.immunomedics.com/pdfs/news/2012/pr01182012.pdf ). According to the American Cancer Society, pancreatic cancer is the 10 th most common cancer diagnosis among men and the 9 th most common among women in the U.S. In 2013, an estimated 45,220 new cases will be diagnosed nationwide. The malignancy is one of the deadliest cancer types, accounting for about 7% of all cancer deaths and is the fourth leading cause of cancer death among both men and women. In 2013, approximately 38,460 people are expected to die from pancreatic cancer nationwide. The prognosis of pancreatic cancer is largely determined by the stage of the disease at diagnosis, with median survival ranges from 4.5 months for the most advanced stage to 24.1 months for the earliest stage. However, only about 7% of pancreatic cancer cases are diagnosed at the early stages. It is, therefore, generally recognized that better tests to diagnose pancreatic cancer earlier, before it has metastasized, are needed.